Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
暂无分享,去创建一个
R. Neve | R. Mackman | Xiaowu Chen | Tetsuya Kobayashi | Hai-Kui Yang | K. Babaoglu | L. Lad | Saritha Kusam | David Sperandio | A. Niedziela-Majka | M. Hung | D. Jin | Kristyna M. Elbel | E. Kan | Z. Newby | E. Lansdon | Nate Larson | B. Jiang | Chin Tay | Vangelis Aktoudianakis | Gregory Chin | B. Corkey | Jinfa Du | Ruben Martinez | J. Zablocki | Kim Jordan | Heather Webb | J. Bates | M. Mish | Sammy Metobo | A. Sapre | Wanchi Fung | G. Eisenberg | Sophia L Shevick | D. Breckenridge | Magdeleine Hung
[1] A. Stathis,et al. BET Proteins as Targets for Anticancer Treatment. , 2018, Cancer discovery.
[2] G. Choi,et al. BET Inhibitors as Anticancer Agents: A Patent Review. , 2017, Recent patents on anti-cancer drug discovery.
[3] A. Brasier,et al. Drug Discovery Targeting Bromodomain-Containing Protein 4 , 2017, Journal of medicinal chemistry.
[4] Y. Taniguchi. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins , 2016, International journal of molecular sciences.
[5] B. Turk,et al. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms , 2016, Proceedings of the National Academy of Sciences.
[6] Yan Zhang,et al. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. , 2016, Journal of medicinal chemistry.
[7] Junwei Shi,et al. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.
[8] Bhairavi Tolani,et al. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors , 2013, Oncogene.
[9] Andrew J. Bannister,et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms , 2014, Leukemia.
[10] R. Prinjha,et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. , 2014, Blood.
[11] S. Knapp,et al. Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.
[12] S. Knapp,et al. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. , 2013, MedChemComm.
[13] Tony Kouzarides,et al. Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.
[14] David M. Wilson,et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.
[15] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[16] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[17] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[18] H. Hellinga,et al. Thermodynamic analysis of ligand-induced changes in protein thermal unfolding applied to high-throughput determination of ligand affinities with extrinsic fluorescent dyes. , 2010, Biochemistry.
[19] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[20] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[21] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[22] C. Chiang,et al. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4 , 2009, F1000 biology reports.
[23] Jonathan Bard,et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.
[24] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.